Recently, Laviana Pharma (Europe) Division – Laviana Pharma SAS – was officially inaugurated in Lyon, France. With the establishment of this European branch, Laviana Pharma 's international business strategy has taken another significant step forward, significantly enhancing the brand influence of Laviana Pharma within the global pharmaceutical industry. This marks a solid foundation for further deepening our presence in international markets.
Lyon, as France's second-largest city, boasts an advantageous location that not only places it in the limelight for its rich history and culture but also makes it a key hub for biopharmaceutical innovation in Europe. The European headquarters is situated in the heart of the Presqu’île Peninsula, Lyon. The Île de la Cité is one of Lyon's most vibrant and bustling districts, nestled between the Rhone and the Saône rivers, and hailed as the "heart" of the city. This region serves not only as a bustling commercial and financial hub but also boasts an abundance of cultural heritage and modern infrastructure, making it one of Lyon's most iconic neighborhoods.
Laviana Pharma (Europe) will focus on technological innovation and commercial application of global pharmaceutical processes, dedicated to providing efficient and high-quality medicinal research and production services for European clients. This move not only bolsters Laviana Pharma competitiveness in the European market but also facilitates the company's push towards technological innovation and enhanced services, thereby creating more value for clients.
As a rapidly growing market in the global pharmaceutical industry, Europe has long been a strategic priority for Laviana Pharma globalization efforts. Laviana Pharma not only participated in the recently concluded German ChemSpecEurope2024 and Swiss BOSBasel2024 exhibitions but will also attend the upcoming Italian CPHIMilan exhibition to showcase its comprehensive strength in the pharmaceutical industry.
Laviana Pharma delves into the European market, offering an all-round integrated service for small molecule drug development and manufacturing (CDMO). Enabling clients by enhancing R&D efficiency, reducing production costs, controlling risks, and introducing continuous reaction technologies as well as green advanced manufacturing techniques, enables efficient empowerment in areas such as process optimization, production design, and innovative chemical synthesis routes, rendering a comprehensive CDMO service for small molecule drugs.
In the ongoing process of global economic integration, Laviana Pharma actively explores new growth domains and opportunities for collaboration. As the gateway to Europe, the European subsidiary will accelerate the company's expansion in international markets. In the future, we will continue to enhance our investments in research and technology, fostering multidisciplinary innovation and development, providing global clients with even more efficient, high-quality, and environmentally sustainable services, maximizing customer value. Become a flagship CDMO enterprise.